Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Advanced Rare Tumors
NCT06683846Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in Extramammary Paget's disease of the scrotum (EMPD), Paraganglioma (PGL), pheochromocytoma, renal angiomyolipoma (AML), perivascular epithelioid cell tumor (PEComa), sponsored by Fudan University. Started Nov 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
Extramammary Paget's disease of the scrotum (EMPD)Paraganglioma (PGL)pheochromocytomarenal angiomyolipoma (AML)perivascular epithelioid cell tumor (PEComa)
Beyond the preview
Go deeper on NCT06683846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683846.